![ASSESSMENT OF ECONOMIC, CLINICAL AND HUMANISTIC OUTCOMES OF PATIENTS WITH ACUTE CORONARY SYNDROME IN THE CARDIAC REHABILITATION PROGRAM Â ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Similar to CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area: (FCA 701/ 48), Cardiovascular Pharmacy, Reference No under NIH KKM MRG-2007-11 Viva lawrence 2011
Similar to CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area: (FCA 701/ 48), Cardiovascular Pharmacy, Reference No under NIH KKM MRG-2007-11 Viva lawrence 2011 (20)
Recently uploaded
Recently uploaded (20)
CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area: (FCA 701/ 48), Cardiovascular Pharmacy, Reference No under NIH KKM MRG-2007-11 Viva lawrence 2011
- 1. Viva-Voce Presentation 2011 CRP Study 2008-2010 Date: 21 st April 2011 Time: 3.00pm Venue: USM
- 12. METHODOLOGY
- 15. CCRP CONTROL MCRP Inpatient Outpatient
- 16. EQ-5D Utility Score A Comparison of Preference-based from EQ-5D and SF-36 SF-6D program in SPSS by Sheffield University ScHARR Estimating a preference-based index from the SF-6D SF-36 SF-6D Utility Score
- 18. RESULTS
- 19. Screening and Recruitment process from Jan-Dec 2008
- 20. At baseline there were no difference in demographic, socioeconomic background, or physical characteristic data
- 21. Clinical & Physical Characteristic
- 24. Nnot MCRP
- 26. Mean Differences after 12 months follow up (MCID of 20 points)
- 27. MCRP CCRP control r = 0.805, p<0.01
- 28. ICER = Incremental cost annually / Incremental Utility Score How much it cost (unit per health benefit)?
- 30. MCRP group
- 34. CONCLUSION
- 41. THANK YOU Sarawak General Hospital It is not the number that count, but the heart….
Editor's Notes
- Retrieving previous history of medication- home, GP, herbal, supplements and so forth. Brief of his/her condition and what have been done Early education of medication given: IV administration, Enoxaparin, infusion GTN, Dopamine, Dobutamine, Midazolam, Morphine, drips, Heparin, amiodarone etc. Oral medication : aspirin, metoprolol, ACEinhibitor, statin, warfarin Early intervention of Side effect of drugs administered. Such as Aspirin, Heparin, Amiodarone, Enoxaparin
- BRUM study. Nonadherence to prescribed medications bypatients with coronary heart disease (CHD) is associated with an increased incidence of adverse cardiovascular events, but it is not known whether self-reported nonadherence can identify patients at greatest risk of such events. Nonadherence to physician treatment recommendations is an increasingly recognized cause of adverse outcomes and increased health care costs, particularly among patients with cardiovascular disease
- Clinical & Physical Characteristic
- Several dimensions of HRQOL measures were found inproved in MCRP. Comparison of mean difference from baseline MCRP (+10.57; 95%CI: -2.09, 23.23) Reported less bodily pain (BP) than CCRP (+3.72, 95%CI:-8.94, 16.39) and Control (-4.16, 95%CI: -14.92, 6.59).
- Results For a 0-100 score and MCID values from -40 to -10, the difference in success rate between arms ranges from 7.9% to 9.9% (ESÂ =Â 0.25) and from 15.9% to 19.7% (ESÂ =Â 0.50). For PASS values from 20 to 50, the difference in success rate between arms ranges from 7.1% to 9.9% (ESÂ =Â 0.25) and from 15.6% to 19.7% (ESÂ =Â 0.50).Conclusion The MCID or PASS value has a low impact on the difference in the success rate between the arms in a trial. Tubach, F., Giraudeau, B., & Ravaud, P. (2009). The variability in minimal clinically important difference and patient acceptable symptomatic state values did not have an impact on treatment effect estimates. Journal of Clinical Epidemiology, 62(7), 725-728. The minimal important difference (MID), from the patient perspective, can be defined as &quot;the smallest difference in score in the domain of interest which patients perceive as beneficial and which would cause clinicians to consider a change in patient's management&quot;. (Jaeschke et al., 1989; Fayers & Machin, 2007).
- BRUM study. Nonadherence to prescribed medications bypatients with coronary heart disease (CHD) is associated with an increased incidence of adverse cardiovascular events, but it is not known whether self-reported nonadherence can identify patients at greatest risk of such events. Nonadherence to physician treatment recommendations is an increasingly recognized cause of adverse outcomes and increased health care costs, particularly among patients with cardiovascular disease
- Table 3.3 Rx RM 3143, MCRP 3214 CCRP 2151 control